Among patients with #HepatocellularCarcinoma beyond the Milan criteria who underwent #LiverTransplant, an immune checkpoint inhibitor–based pretransplant strategy was associated with better survival and lower recurrence vs therapy without immune checkpoint inhibitors. ja.ma/4hFlgbb

Among patients with nonmetastatic #HeadNeckCancer receiving radiation therapy, financial toxicity was associated with worse quality of life and substantial out-of-pocket expenses. ja.ma/4dzMI8Z

This review examines ovarian metastases from colorectral cancer and the potential role of surgical resection of metastatic disease. ja.ma/4iKDA4S

Among adults in China and the UK, modifiable lifestyle factors and health conditions accounted for most of the male-female #Cancer incidence gap in China but only a smaller fraction in the UK. ja.ma/4ygALxm

In a recent @jamaoncology.com publication, @biagioricciutimd.bsky.social and @danafarber.bsky.social researchers found that first-line chemo-immunotherapy improved survival outcomes compared with PD-(L)1 inhibitor monotherapy in advanced NSCLC with PD-L1 ≥50%. Read more: bit.ly/4vVbhVh

We present a new type of biomarker - based on a math equation rather than a genetic or transcriptomic assay. By capturing dynamic patterns in PSA during the first treatment cycle, we can predict prostate cancer outcomes across disease settings, paving the way for personalized treatment schedules.

JAMA Oncology@jamaoncology.com · 2mo ago

In patients with #ProstateCancer receiving #AdaptiveTherapy, mathematical biomarkers from first-cycle prostate-specific antigen (#PSA) dynamics predicted time to progression and overall survival better than standard PSA metrics. ja.ma/4wbDsyf

Writing in JAMA Oncology, YSM researchers report that prostate-specific membrane antigen positron emission tomography (PSMA-PET) #imaging could shift #prostate #cancer treatment patterns by detecting previously hidden metastases. @jamaoncology.com Learn more: medicine.yale.edu/publication-...

Prebiopsy #MRI use before #ProstateCancer biopsy increased in the US from 2017 to 2026, reaching 64.1% of biopsy-naive patients, but uptake remained incomplete. ja.ma/4gPW16U

Editorial: In HPV 16–positive recurrent or metastatic #HeadAndNeckCancer, PDS0101 plus pembrolizumab demonstrated activity in immune checkpoint inhibitor–naive disease but not after prior immune checkpoint inhibitor exposure. ja.ma/4xW1IWP

Meta-analysis: In #HeadAndNeckCancer with programmed cell death 1 ligand 1 combined positive score <1, #ImmuneCheckpointInhibitors were likely associated with reduced survival, including significantly reduced overall survival in recurrent or metastatic disease. ja.ma/46uMnAC

In #HPV16-positive recurrent or metastatic #HeadAndNeckCancer, PDS0101 plus #Pembrolizumab showed antitumor activity and manageable safety in immune checkpoint inhibitor–naive patients, but no objective responses in resistant patients. ja.ma/4xVtvql

In persistent, recurrent, or metastatic #CervicalCancer, first-line #Pembrolizumab plus chemotherapy with or without bevacizumab maintained overall survival and progression-free survival benefit at 5 years, with no new safety signals observed. ja.ma/3UHjheC

A 76-year-old man presented to the emergency department with 5 days of worsening dyspnea at rest, lower extremity edema, fatigue, confusion, and poor oral intake. What is your diagnosis? ja.ma/4cvl6kY

Man With Undifferentiated Shock and Hypoxemic Respiratory Failure

A 76-year-old man presented to the emergency department with 5 days of worsening dyspnea at rest, lower extremity edema, fatigue, confusion, and poor oral intake. What is your diagnosis?

ja.ma

Among children with relapsed or refractory #BCellAcuteLymphoblasticLeukemia, bicistronic CD19/CD22 #CARTCell therapy was associated with high rates of minimal residual disease–negative remission and durable event-free survival. ja.ma/4hc7VYK

Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia

This nonrandomized clinical trial examines the safety and efficacy of bicistronic CD19/CD22 chimeric antigen receptor T-cell therapy in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

ja.ma

Among patients with #ERBB2-positive #BreastCancer, neoadjuvant anbenitamab plus HB1801 was associated with a higher total pathologic complete response rate vs trastuzumab, pertuzumab, and docetaxel, with similar grade 3 or 4 toxic effects. ja.ma/46FBax8

💬 Editorial: In pediatric #AcuteLymphoblasticLeukemia, bicistronic CD19/CD22 #CARTCell therapy was associated with durable remission despite limited persistence, challenging the view that prolonged CAR T-cell surveillance is always required. ja.ma/464VxDP

CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

In this issue of JAMA Oncology, Wan et al1 report a cohort of 261 pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with bicistronic anti-CD19/CD22 chimeric antigen receptor (CAR) T-cell therapy. This nonrandomized clinical trial achieved remarkable...

ja.ma

📝 JAMA Oncology Patient Page: Supplements and Wellness Products During #Cancer Care This Patient Page discusses safety when taking supplements and wellness products during cancer treatment. ja.ma/3SPjlZi

Supplements and Wellness Products During Cancer Care

This JAMA Oncology Patient Page discusses safety when taking supplements and wellness products during cancer treatment.

ja.ma

📑 This JAMA Oncology review discusses #Chemotherapy decision-making support tools and updated evidence guiding therapeutic decision-making among older adults with early-stage #BreastCancer. ja.ma/4x96mzy

Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer

This narrative review discusses chemotherapy decision-making support tools and updated evidence guiding therapeutic decision-making among older adults with early-stage breast cancer.

ja.ma

In #CancerCare, biosimilar entry for bevacizumab, rituximab, and trastuzumab was associated with lower reference product prices and market share, along with lower payer and patient costs. ja.ma/4ig46mA

#ColorectalCancer mortality declined nationally among US adults aged ≥45 years from 2000 to 2019, but county-level disparities persisted, with some counties exceeding 100 deaths per 100 000 among American Indian or Alaska Native and Black populations. ja.ma/4ymxIDm

In US #Cancer clinical trials, industry sponsors were more likely to focus on single-agent drug therapies, while federal sponsors were more likely to evaluate prevention and supportive care interventions. ja.ma/3TbzUyG

In Denmark, #Meningioma incidence increased from 2010 to 2023, but #Surgery and #Radiotherapy rates remained stable, indicating that more diagnoses did not lead to more treatment. ja.ma/465TUFZ

In US #Cancer clinical trials, industry sponsors were more likely to focus on single-agent drug therapies, while federal sponsors were more likely to evaluate prevention and supportive care interventions. ja.ma/3TgzIhF

Federal and Industry Sponsorship in US Cancer Clinical Trials

This comparative study of cancer clinical trial portfolios assesses differences between federal and industry sponsors in cancer clinical trial research.

ja.ma

A 79-year-old woman with high-risk myelodysplastic syndrome treated with 5-azacitidine presented with painful ulcers on the tongue and right lower extremity. What is your diagnosis? ja.ma/4wVRi9f

Among patients with early #TripleNegativeBreastCancer, tissue-free #ctDNA detection during molecular residual disease surveillance was strongly prognostic for recurrence and supported testing when tumor tissue was unavailable. ja.ma/3S5A0Hu

Among men with #ProstateCancer starting concurrent androgen deprivation therapy and an androgen receptor pathway inhibitor, #MetabolicSyndrome and related abnormalities were frequently documented early, with hypertension the most common outcome. ja.ma/3TW65Cf

Among patients with metastatic #BreastCancer, alert-based digital patient-reported outcome monitoring was associated with lower fatigue at 6 months vs usual care, with improvement exceeding the minimal clinically important difference. ja.ma/4xzjmPF

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone. ja.ma/3UsSpyJ

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone. ja.ma/4wjlR7I

In patients with #ProstateCancer receiving #AdaptiveTherapy, mathematical biomarkers from first-cycle prostate-specific antigen (#PSA) dynamics predicted time to progression and overall survival better than standard PSA metrics. ja.ma/4wbDsyf